DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Summary for Patent: 8,748,577
|Title:||Conjugates of biologically active polypeptides having an increased in vivo half-life|
|Abstract:||Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.|
|Inventor(s):||Besman; Marc (Seattle, WA), Chipman; Stewart (Bainbridge Island, WA), Leung; David (Mercer Island, WA), Singer; Jack (Seattle, WA)|
|Assignee:||Cell Therapeutics, Inc. (Seattle, WA)|
|Patent Claims:||1. A biologically active protein conjugate comprising a biologically active polypeptide coupled via a peptide bond to an amino acid extension comprising from 2 to 75
repeating units of a peptide motif, wherein said peptide motif consists of two residues Asn (N) and one residue of an amino acid selected from the group consisting of Ser (S) and Thr (T), wherein the biologically active polypeptide is human growth
hormone SEQ ID NO:2472, granulocyte macrophage colony stimulating factor (GM-CSF; SEQ ID NO:2462), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF; SEQ ID NOs:2454, 2456, 2458, or 2460), colony stimulating
factor (CSF), platelet derived growth factor (PDGF), tumor necrosis factor (TNF), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), fibroblast growth factor, (FGF), nerve growth factor (NGF), erythropoietin (EPO; SEQ ID NOs:2452,
2480, or 2481), interferon, interferon gamma inducing factor I (IGIF), transforming growth factor beta (TGF-.beta.), RANTES (regulated upon activation, normal T-cell expressed and presumably secreted), macrophage inflammatory protein-1-alpha
(MIP-1-.alpha.), macrophage inflammatory protein-1-.beta. (MIP-1-.beta.), Leishmania elongation initiating factor (LEIF), brain derived neurotrophic factor (BDNF), neurotrophin-2 (NT-2), neurotrophin-3 (NT-3), neurotrophin-4 (NT-4), neurotrophin-5
(NT-5), glial cell line-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF), a soluble tumor necrosis factor (TNF) type II receptor, a soluble tumor necrosis factor (TNF) type I receptor, a soluble IL-1 receptor type II, a soluble IL-4
receptor, a soluble gp120 glycoprotein, a soluble gp160 glycoprotein, an IL-1 receptor antagonist, a coagulation factor, insulin, activated protein C, Factor VII, collagenase, agalsidase-beta, dornase-alpha, alteplase, pegylated-asparaginase,
asparaginase, or imiglucerase, and wherein said biologically active protein conjugate has an increased plasma half-life compared to the plasma half-life of the unmodified biologically active polypeptide.
2. The biologically active protein conjugate of claim 1, wherein said peptide motif has an amino acid sequence selected from the group consisting of SNN, NSN, NNS, TNN, NTN, and NNT.
3. The biologically active protein conjugate of claim 1, wherein said amino acid extension is situated at the N-terminus with respect to said biologically active polypeptide, is situated at the C-terminus with respect to said biologically active polypeptide, or is situated at both the N- and C-termini with respect to said biologically active polypeptide.
4. The biologically active protein conjugate of claim 1, wherein said interferon is selected from the group consisting of a beta-interferon (SEQ ID NO:2468) and a gamma-interferon (SEQ ID NO:2470).
5. The biologically active protein conjugate of claim 1, wherein said biologically protein conjugate further comprises a leader sequence.
6. The biologically active protein conjugate of claim 5, wherein the leader sequence is the Schizosaccharomyces pome acid phosphatase (PHO) leader sequence (amino acid residues 1 to 18 of SEQ ID NO:2450).
7. The biologically active protein conjugate of claim 1, wherein said biologically active protein conjugate further comprises a linker.
8. A composition comprising the biologically active protein conjugate of claim 1 and a pharmaceutically effective carrier.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Merck||ELSPAR||asparaginase||VIAL||101063||001||1978-01-10||Start Trial||Cell Therapeutics, Inc. (Seattle, WA)||2025-01-25||RX||search|
|Advance Biofactures||SANTYL||collagenase||VIAL||101995||001||1965-06-04||Start Trial||Cell Therapeutics, Inc. (Seattle, WA)||2025-01-25||RX||search|
|Genentech||ACTIVASE||alteplase||VIAL; SINGLE-USE||103172||001||1987-11-13||Start Trial||Cell Therapeutics, Inc. (Seattle, WA)||2025-01-25||RX||search|
|Genentech||ACTIVASE||alteplase||VIAL; SINGLE-USE||103172||002||1987-11-13||Start Trial||Cell Therapeutics, Inc. (Seattle, WA)||2025-01-25||RX||search|
|Genentech||CATHFLO ACTIVASE||alteplase||VIAL||103172||003||1987-11-13||Start Trial||Cell Therapeutics, Inc. (Seattle, WA)||2025-01-25||RX||search|
|Genzyme||FABRAZYME||agalsidase beta||VIAL; INTRAVENOUS||103979||001||2003-04-24||Start Trial||Cell Therapeutics, Inc. (Seattle, WA)||2025-01-25||RX||Orphan||search|
|Genzyme||FABRAZYME||agalsidase beta||VIAL; INTRAVENOUS||103979||002||2003-04-24||Start Trial||Cell Therapeutics, Inc. (Seattle, WA)||2025-01-25||RX||Orphan||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Publication Date|
|South Africa||200707006||Nov 26, 2008|
|World Intellectual Property Organization (WIPO)||2006081249||Aug 03, 2006|
|World Intellectual Property Organization (WIPO)||2006081249||Feb 01, 2007|
|World Intellectual Property Organization (WIPO)||2006081249||Jul 26, 2007|
|World Intellectual Property Organization (WIPO)||2006081249||Sep 13, 2007|
|United States of America||2009298762||Dec 03, 2009|
|United States of America||2012252717||Oct 04, 2012|
|>Country||>Patent Number||>Publication Date|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.